LATEST PRESS RELEASES

438 views6 min read

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

Revive Therapeutics
Building specialty psilocybin-based product pipelineEvaluating potential for neuropsychiatric indications for clinical studies in 2022TORONTO, Nov. 03, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therap... Read More...
1421 views5 min read

Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients

Mydecine Innovations Group
DENVER, Nov. 03, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced the filing of a technology patent that allows for the creation of formulations th... Read More...
158 views4 min read

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

Bright Minds Biosciences
VANCOUVER, British Columbia, Nov. 03, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that The Nasdaq Stock Market LLC has approved the lis... Read More...
Financials254 views2 min read

Aion Therapeutic Files Financials

Aion Therapeutic
Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").Management of... Read More...
CalendarFinancials1290 views4 min read

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, November 16, 2021 at 8:30 AM ET

Field Trip Health
TORONTO, Nov. 02, 2021 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended September 30, 2021, after market close on Monday, November 15, 2021. Th... Read More...
175 views8 min read

Allied Corp Launches “Allied Inside™” Approach for Wholesale Product Offering With Trademark Filing

Allied
KELOWNA, British Columbia, Nov. 02, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the launch of the Allied Inside™ approach to wholesale cannabis product offering. On October 30, 2021 Allied filed trademark for protection of the words and logo mark that demarks the Allied Inside™ product. About Alli... Read More...
1094 views7 min read

Red Light Holland Appoints New Chief Financial Officer

Red Light Holland
● David Ascott has been appointed as Chief Financial Officer of Red Light Holland, a Psychedelics Company with more than $28 million of working capital*● Bruce Linton, heavily involved in the CFO hiring process "ecstatic" to have Mr. Ascott join CEO Todd Shapiro and the Red Light Holland Team Toronto, Ontario--(Newsfile Corp. - November 1... Read More...
LOI54 views5 min read

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

Mind Cure Health
VANCOUVER, BC, Oct. 28, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce the signing of a non-binding letter of intent ("LOI") with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF) ("Awakn"), a biotechnology compa... Read More...
Financials914 views4 min read

PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022

PharmaTher Holdings
TORONTO, Oct. 27, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released its business update and financial results for the three months ended August 31, 2021.  All amounts are stated in Canadian dollars unless otherwise indicated.   “To dat... Read More...
56 views3 min read

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

Silo Pharma
Englewood Cliffs, NJ, Oct. 27, 2021 -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into a sponsored research agreement with Columbia University pursuant to which Silo has been granted an option to license certain ass... Read More...
1232 views3 min read

Novamind Unveils Stealth Mode Investment in Alto Neuroscience

Novamind
TORONTO, ON / ACCESSWIRE / October 22, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to unveil Alto Neuroscience ("Alto"), a clinical-stage biopharmaceutical company, as its previously announced stealth mode investment. In June 2021, Novami... Read More...
46 views8 min read

Allied Corp Signs Major Supply Agreement With US Multi State Operator (MSO) and Sales Agreement for Allied’s CBD Brands

Allied
KELOWNA, British Columbia, Oct. 20, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of what we believe to be another major supply agreement for the 2022 calendar year. Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to cou... Read More...
1045 views8 min read

Allied Corp Signs Major Supply Agreement With Us Multi State Operator (mso) And Sales Agree-ment For Allied’s Cbd Brands

Allied
Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of what we believe to be another major supply agreement for the 2022 calendar year.Kelowna, BC --News Direct-- Allied CorpAllied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of what we believe to be another major... Read More...
52 views6 min read

Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

Field Trip Health
TORONTO, Oct. 19, 2021 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their Seattle clinic, their sixth in the United States, along with the recent opening of a location in Fredericton, NB, and the imminent opening... Read More...
146 views4 min read

Global Comedy Star Russell Peters to Have a Psychedelic Journey with Red Light Holland’s Natural Psilocybin Truffles and Red Light Holland’s Therapist in Amsterdam

Red Light Holland
● Red Light Holland to live stream an intimate Russell Peters performance in front of a live audience, after he completes his journey, on multiple social media accounts● Red Light Holland to document Russell Peters moments in The Netherlands, as he will be accompanied by a camera crewToronto, Ontario--(Newsfile Corp. - October 15, 2021) -... Read More...
Joint Venture30 views10 min read

Ketamine Wellness Centers Partners with Veterans Affairs (VA) Community Care Network to Provide Free Ketamine Treatments to Veterans

Delic Holdings
Nation's Largest Clinic Chain's Partnership with Illinois and Minnesota Chapters to Provide Ketamine Treatments for PTSD, Depression and Pain at No Out-of-Pocket Cost VANCOUVER, BC, Oct. 14, 2021 - Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source) the leading psychedelic wellness platf... Read More...
24 views4 min read

Psyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker “PSYGF”

Psyence Group
TORONTO, Oct. 13, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that, effective today, its common shares have been approved for trading on the OTCQB® Venture Market (... Read More...
1325 views7 min read

Red Light Holland Expands the iMicrodose Brand and Unveils New iMicrodose Products: Triniti, Uniti and Mindfuli

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland"), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce they have unveiled new iMicrodose Products powered by Red Light... Read More...
496 views3 min read

Novamind Launches New Psychedelic Palliative Care Program

Novamind
Specialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illnessTORONTO, ON / ACCESSWIRE / October 7, 2021 /Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind"), a leading mental health company specialized in psychedelic medicine, is pleased to launch Psychedelic P... Read More...
248 views4 min read

Blackhawk Growth’s MindBio Therapeutics Brings Digital Mental Health Technology To Psychedelics Clinical Trials

Blackhawk Growth
Calgary, Alberta --News Direct-- Blackhawk Growth Corp.Vancouver, British Columbia - TheNewswire – October 7, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics is developing a mental health technology platform to integrate with psychedelic ... Read More...
329 views8 min read

Allied Corp Announces Signing of Supply Contracts of 85,000, 40,000 and 24,000 Kilograms for the 2022 Calendar Year

Allied
KELOWNA, British Columbia, Oct. 07, 2021 -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce the signing of supply contracts for the 2022 calendar. Allied will be only providing cannabis flower after the Colombian government allows it and will provide supply only to countries where it is legal to sell into (fo... Read More...
507 views1 min read

Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Silo Pharma
Englewood Cliffs NJ, Oct. 07, 2021 -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with ... Read More...
59 views8 min read

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Lobe Sciences
Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment ExperienceVancouver, British Columbia--(Newsfile Corp. - October 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Krysalis VX Innovations Inc. ("Krysalis")... Read More...
1286 views6 min read

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

PharmaTher Holdings
TORONTO, Oct. 06, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial of Ketamine for the treatment of Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease. Patient sc... Read More...
286 views0 min read

Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference

Bright Minds Biosciences
VANCOUVER, British Columbia, Oct. 06, 2021 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer of Bright ... Read More...
41 views8 min read

Delic Labs Applies for Dealer’s License to Commercialize Psychedelics Research, Health Exemption to Test MDMA and LSD

Delic Holdings
License Allows Authority to Work with Additional Banned Substances and Market the Research for Medical Purposes VANCOUVER, BC, Oct. 6, 2021 - Delic Holding Corp Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), the leading psychedelic wellness platform, today announced Delic Labs has applied for a He... Read More...
1155 views11 min read

Red Light Holland Expands Product Offerings and Rebrands Maka Truffles as a Responsible Use Psychedelic

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland"), an Ontario-based corporation engaged in the production, growth, and sale of a premium brand of magic truffles, is pleased to announce they have expanded their product offerings with Maka magic truf... Read More...
36 views5 min read

Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

Mydecine Innovations Group
DENVER, Oct. 05, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being con... Read More...
192 views7 min read

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

Cybin
Promotion of Certain Members of Management Team and Engagement with a Capital Markets Communications FirmTORONTO, October 01, 2021--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Ami... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!